This crosstalk could also provide an explanation for the partial inhibition of AKT following treatment of CLL cells and lymphoma cell lines with the BTK inhibitor ibrutinib in vitro and in vivo [27,28,29,30]. This evidence concerns the gene AKT1 and lymphoma.